New York-based pharmaceutical services platform Petauri Health has acquired The Kinetix Group (TKG), a strategic advisory and medical affairs agency. TKG provides services such as access marketing, health economics research, and care pathway development to life sciences companies. TKG’s founders, John Strapp and Sarah McNulty, will continue to lead the company. Petauri aims to overcome healthcare barriers and accelerate patient access to medical advancements through collaborations with industry experts. TKG’s market access expertise and strong customer relationships make it an ideal first acquisition for Petauri, according to CEO Dan Renick.
Petauri Health, a New York–based, purpose-built pharmaceutical services platform, announced today that it has acquired The Kinetix Group, also known as TKG.
Founded by John Strapp and Sarah McNulty, The Kinetix Group is a strategic advisory, access marketing, and medical affairs agency that partners with life sciences companies to effectively engage with health systems, payers, and patients. The company offers a range of services, including strategic consulting, access marketing and branding, health economics and outcomes research, organizational design and transformation, and care pathway development, among others. The founders will continue to serve as leaders of the company. TKG is headquartered in New York City and employs more than 100 industry professionals supporting over 20 clients, including 7 of the top 10 pharmaceutical companies.
Remarking on the collaboration, cofounder McNulty said, “We’re excited to be a part of the Petauri platform and to be working alongside our industry colleague and friend Dan Renick. The time could not be more critical, as scientific innovation continues to outpace society’s ability to pay for it, resulting in widespread healthcare inequities that must be resolved.” Cofounder Strapp added, “Once assembled, Petauri’s diverse and accomplished industry experts will seek to partner with clients across numerous commercialization domains to overcome marketplace barriers and speed patient access to medical advances.” TKG was advised by Technology Holdings on this strategic sale to Petauri Health.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“John, Sarah, and the TKG team have a stellar reputation for designing critical solutions for new and mature brands, and should continue to positively impact healthcare, now and in the future,” said Dan Renick, Petauri CEO. “Their best-in-class market access expertise and deep customer relationships across the healthcare ecosystem make TKG the ideal first acquisition for Petauri.”
Source: BioSpace